Encora Therapeutics Receives FDA 510(k) Clearance for Encora X1™, a Breakthrough Wearable Device for Essential Tremor
Encora Therapeutics, a leader in non-invasive neuromodulation technology, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Encora X1™.
Encora Therapeutics Names Nadim Yared as Chairman and Chief Executive Officer
Encora Therapeutics, a clinical-stage medtech company developing a neuromodulation therapy for movement disorders, today announced the appointment of Nadim Yared as Chairman and Chief Executive Officer, effective immediately. Co-Founder and prior CEO Daniel Carballo will remain with the company and assume the role of VP of Strategy. Under Nadim’s leadership, Encora will focus on advancing late-stage clinical programs, strengthening regulatory and reimbursement pathways, and expanding strategic partnerships to accelerate patient access.
Encora Therapeutics’ Abstract at 2025 American Academy of Neurology (AAN) Annual Meeting Selected for Merit as “Abstract of Distinction”
Encora Therapeutics today announced that its abstract, Safety and Efficacy of a Wrist-worn Vibratory Stimulation Wearable for Upper Limb Tremor Reduction in Essential Tremor (ULTRE): A Randomized, Controlled Trial, was honored as an “Abstract of Distinction” by the American Academy of Neurology (AAN) and the Science Committee at the recent AAN 2025 Annual Meeting. This distinction was awarded to the single top-rated abstract out of over 300 in its topic category of Movement Disorders “based on the quality of study and interest to the neurologic community”.
Encora Therapeutics Successfully Completes ULTRE Clinical Trial Evaluating Novel Wrist-Worn Wearable for Essential Tremor
Encora Therapeutics is pleased to announce the successful completion of the ULTRE (Upper Limb Tremor Reduction in Essential Tremor) clinical trial. This study evaluated the safety, tolerability, and efficacy of Encora's wrist-worn stimulation device for patients with essential tremor (ET), a tremor disorder affecting the upper limbs of an estimated 7.6 million Americans. Current treatment options for ET are often inadequate and poorly tolerated, underscoring the critical need for new therapeutic approaches.
